Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment

In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component o...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & developmental immunology 2010-01, Vol.2010 (2010), p.1-17
Main Authors: Hamšíková, Eva, Vonka, Vladimír, Humlová, Zuzana, Roth, Zdeněk, Šterzl, Ivan, Králíková, Petra, Klamová, Hana, Janatková, Ivana, Malíčková, Karin
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
Benzamides
C-Reactive Protein - analysis
Complement System Proteins - analysis
Dasatinib
E coli
Female
Humans
Hydroxyurea - therapeutic use
Imatinib Mesylate
Immune system
Immunity, Innate
Immunoglobulins - blood
Immunologic Factors - therapeutic use
Immunology
Interferon-alpha - therapeutic use
Interleukin-6 - blood
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
Longitudinal Studies
Lupus
Male
Mathematical models
Middle Aged
Piperazines - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - therapeutic use
T-Lymphocytes - metabolism
Teaching hospitals
Thiazoles - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.
ISSN:1740-2522
2314-8861
1740-2530
2314-7156
DOI:10.1155/2010/137320